EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lefamulin harbors promising anti-tuberculosis activity against multidrug-resistant Mycobacterium tuberculosis isolates

Jing Wu, Yuanfei Ji, Weihe Zhang, Siyi Chen, Yao Dong, Xia Yu iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.02250-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Jing Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medica…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Tuberculosis, Multidrug-Resistant, Polycyclic Compounds. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Public Health Experts Project, Outstanding Young Scientific and Technological Workers in Tongzhou District.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug-resistant tuberculosis (MDR-TB) is often associated with poor clinical outcomes. This study evaluated the in vitro activity of lefamulin (LEF) and intracellular activities against Mycobacterium tuberculosis . In this study, we evaluated the potential of LEF as a new drug candidate for treating M. tuberculosis infections, including MDR-TB. The antimicrobial susceptibility testing was performed to determine the minimum inhibitory concentrations (MICs) of LEF against 132 clinical isolates of M. tuberculosis . The intracellular activity of LEF and its interaction with other anti-tuberculosis drugs were also evaluated using M. tuberculosis H37Rv. From the 132 M . tuberculosis clinical isolates , the MIC 50 and MIC 90 were 0.5 µg/mL and 1 µg/mL, respectively. The tentative epidemiological cut-off (ECOFF) against LEF was defined at 1 µg/mL. After 5 days of incubation, LEF at 2 µg/mL inhibited 89.88% ± 1.73% of intracellular bacterial growth, which was comparable with the inhibitory rate of 94.29% ± 1.32% achieved by INH at 2 µg/mL. In addition, a synergy between LEF and bedaquiline (BDQ) was observed with a fractional inhibitory concentration index = 0.5. Furthermore, LEF showed no correlation with resistance to 10 anti-tuberculosis drugs. The minimum bactericidal concentration/MIC of LEF values suggested that it is a bacteriostatic drug against M. tuberculosis , and the bactericidal activity is mainly characterized by a concentration-dependent pattern. LEF has potent inhibitory activities against M. tuberculosis in vitro as well as in macrophages. Furthermore, the synergistic effect with BDQ also favors LEF as a promising drug candidate for tuberculosis treatment, especially for MDR-TB. IMPORTANCE Lefamulin (LEF), the first systemic pleuromutilin antibiotic approved for human use, exhibits broad-spectrum activity against Gram-positive bacteria. However, its in vitro activity against Mycobacterium tuberculosis ( Mtb ) remains unexplored. This study evaluated the potential of LEF for treating Mtb infections, including multidrug-resistant tuberculosis. Our findings demonstrate that LEF possesses potent bacteriostatic activity against Mtb in vitro and exhibits synergistic effects when combined with bedaquiline. These results suggest LEF as a promising therapeutic candidate for tuberculosis treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsTuberculosis, Multidrug-ResistantPolycyclic CompoundsMicrobial Sensitivity TestsHumansDrug Resistance, Multiple, BacterialDrug SynergismAnimalsDiterpenesThioglycolates

Stichwörter der Autor:innen

Mycobacterium tuberculosisantimicrobial activityintracellular activitylefamulin

Substanzen

Antitubercular AgentslefamulinPolycyclic CompoundsDiterpenesThioglycolates

Autor:innen und Institutionen

  • National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institu…

ORCID-Profile: Xia Yu

Förderung

  • Beijing Public Health Experts Project
  • Outstanding Young Scientific and Technological Workers in Tongzhou District

Zitieren

APA

Wu, J., Ji, Y., Zhang, W., Chen, S., Dong, Y., & Yu, X. (2025). Lefamulin harbors promising anti-tuberculosis activity against multidrug-resistant Mycobacterium tuberculosis isolates. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02250-25

Vancouver

Wu J, Ji Y, Zhang W, Chen S, Dong Y, Yu X. Lefamulin harbors promising anti-tuberculosis activity against multidrug-resistant Mycobacterium tuberculosis isolates. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02250-25

BibTeX
@article{Wu2025,
  author = {Wu, Jing and Ji, Yuanfei and Zhang, Weihe and Chen, Siyi and Dong, Yao and Yu, Xia},
  title = {Lefamulin harbors promising anti-tuberculosis activity against multidrug-resistant Mycobacterium tuberculosis isolates},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.02250-25}
}
Kostenlos starten →